ASX healthcare companies gain key validation through conference presentations and peer-reviewed journal publications. Pic: Getty Images <\/p>\n
Presentations at specialist medical conferences along with publications in peer-reviewed journals offer important validation for ASX healthcare companies
\nAlterity is presenting updates on ATH434, its Phase III-ready asset for MSA, at international neurology and imaging conferences
\nClever Culture, which is building global visibility for its APAS Independence with big pharma customers, is presenting at international conferences<\/p>\n
\u00a0<\/p>\n
For healthcare companies, presentations at specialist medical and industry conferences along with publication in peer-reviewed journals place their clinical research programs and technology platforms in front of key stakeholders.<\/p>\n
In sectors such as diagnostics, drug development and medical devices, peer-reviewed journals, conference posters and podium presentations are important for building credibility, validation, partnership formation and ultimately commercial adoption.<\/p>\n
But not every company gets a seat at the table. Conference programs are highly competitive \u2014 abstracts are often blindly evaluated by scientific committees, and high-profile sessions are reserved for invited experts.<\/p>\n
Publication in peer-reviewed journals also requires independent external review, making it the gold standard for data credibility.<\/p>\n
\u00a0<\/p>\n
Ensuring the science stacks up<\/p>\n
Portfolio manager Reece O\u2019Connell from Summit Biotechnology Fund, one of Australia\u2019s most active biotechnology investment funds, told Stockhead that when investing in biotechnology companies, be careful not to just fall in love with the story.<\/p>\n
\u201cThe market opportunity, team and potential impact are all important, but none of it really matters if the underlying science doesn\u2019t stack up,\u201d he said.<\/p>\n
\u201cThat\u2019s why external independent validation is so important.\u201d<\/p>\n
O\u2019Connell said it was important to know what respected researchers, clinicians and independent committees thought of the work \u2013 is the company\u2019s thesis credible? Is the technology possible? Do the clinicians who would actually use it see a real need for it?<\/p>\n
\u201cOnce those pieces start to line up, then you can look at the commercial side, the market demand, the unit economics, and whether the team has the resources and track record to execute,\u201d he said.<\/p>\n
\u201cPeer-reviewed journals and conference presentations are a good place to start following that trail.<\/p>\n
\u201cIf the science is strong, it should be able to stand up in front of the right people and if\u00a0that validation is missing, investors should probably ask why.\u201d<\/p>\n
\u00a0<\/p>\n
Big month of presentations for Alterity<\/p>\n
Alterity Therapeutics (ASX:ATH)<\/a> will present multiple updates on ATH434, its Phase III-ready asset for Multiple System Atrophy (MSA, at international neurology and imaging conferences in May.<\/p>\n At the International Society for Magnetic Resonance in Medicine annual meeting in Cape Town, Vanderbilt University researcher Dr Paula Trujillo will give an oral presentation on how advanced MRI imaging data, Quantitative Susceptibility Mapping (QSM), detects progressive iron accumulation in early MSA patients<\/a>.<\/p>\n The data was generated through Alterity\u2019s Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History study, together with additional cross-sectional MSA, Parkinson\u2019s Disease and healthy control data.<\/p>\n The bioMUSE study is being run in collaboration with Vanderbilt University Medical Center, under direction of Professor Neurology and principal investigator Dr Daniel Claassen, who was recently appointed Alterity\u2019s chief medical advisor.<\/p>\n The data on QSM imaging showing progressive iron accumulation in early MSA patients also forms the basis of a recently published article in the peer-reviewed journal NeuroImage.<\/p>\n At the Movement Disorder Society of Australia and New Zealand Scientific Meeting in Sydney, Claassen will present poster data from Alterity\u2019s double-blind, placebo-controlled Phase II ATH434-201 study, focusing on how certain biomarkers responded in a new analysis of the trial.<\/p>\n Meanwhile, at the MSA Symposium 2026 in London, CEO Dr David Stamler will provide a clinical update on ATH434 and discuss plans for the company\u2019s planned Phase III trial.<\/p>\n \u201cMSA is a rapidly progressive disease with no approved treatment, and patients and clinicians have been waiting a long time for meaningful progress,\u201d Stamler told Stockhead.<\/p>\n \u201cThis month marks an inflection point for ATH434 with three major scientific meetings, new biomarker validation from our bioMUSE natural history study, and a clearer view of the mechanism behind ATH434\u2019s Phase 2 efficacy.<\/p>\n \u201cAs we move toward our end-of-Phase II FDA meeting and prepare to launch a pivotal Phase III trial, the strength of the data is opening important conversations across the neurology and biopharma community.\u201d<\/p>\n \u00a0<\/p>\n \ufeff\ufeff\u00a0 As the global search for better cancer detection and treatments intensifies, ASX-listed companies spanning diagnostics, imaging and therapeutics are increasingly using medical conferences along with journals to showcase emerging clinical data.<\/p>\n Clinical-stage immuno-oncology company Imugene (ASX:IMU)<\/a> is a regular presenter at major global oncology conferences where emerging immunotherapy and cell therapy data is closely watched by clinicians, researchers and pharmaceutical groups.<\/p>\n In April, Imugene announced data from its lead program azer-cel (azercabtagene zapreleucel) had been selected for an oral presentation at the American Society of Clinical Oncology (ASCO) 2026.<\/p>\n The company most recently had an oral presentation in December 2025 at the American Society of Hematology.<\/p>\n \u201cPresenting data at major oncology conferences and publishing in peer-reviewed journals is critical for building scientific credibility, engaging pharmaceutical partners, and increasing investor confidence,\u201d CEO and managing director Leslie Chong told Stockhead.<\/p>\n \u201cThese forums validate the strength of your science, elevate awareness of your program among key opinion leaders, and can materially influence partnering discussions, financing opportunities, and ultimately the commercial trajectory of a therapy.\u201d<\/p>\n Telix Pharmaceuticals (ASX:TLX)<\/a> is a regular presenter at major nuclear medicine and oncology conferences including ASCO, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and the Australian and New Zealand Society of Nuclear Medicine (ANZSNM).<\/p>\n Telix is one of ASX\u2019s leading radiopharmaceutical companies, developing targeted imaging and therapeutic products across prostate, kidney and brain cancer.<\/p>\n Clarity Pharmaceuticals (ASX:CU6)<\/a> has also been a presenter at major international oncology and nuclear medicine conferences to showcase data from its prostate cancer imaging and theranostics programs.<\/p>\n Most recently Clarity delivered an oral presentation of its Co-PSMA trial \u2014 a head-to-head comparison of diagnostic agent 64-Cu-SAR-bis-PSMA against standard of care Gallium-PSMA-11 \u2013 at the 2026 European Association of Urology Congress.<\/p>\n Data was subsequently accepted for publication in European Urology, a top-tier peer-reviewed journal.<\/p>\n \u201cIt was fantastic to see that trial, conducted independently by Professor Louise Emmett at St Vincent\u2019s Hospital in Sydney, compare our product head-to-head with the current standard-of-care imaging agent,\u201d executive chairman Dr Alan Taylor told Stockhead.<\/p>\n \u201cAcross 50 patients, 64-Cu-SAR-bis-PSMA detected 63 lesions compared to 24 for standard of care and identified disease recurrence in a significantly greater proportion of patients.\u201d<\/p>\n \u00a0<\/p>\n Big pharma showcases Clever Culture\u2019s APAS Independence<\/p>\n
\nCancer plays showcase clinical breakthroughs<\/p>\n